DSM's pharma business, JLL and Patheon to create $ 2 bn behemoth

Private equity firm JLL Partners and Royal DSM have announced the creation of a new company, which will be a leading global contract development and manufacturing organisation (CDMO) for the pharmaceutical industry with anticipated sales of around $ 2 billion. It will be 51% owned by JLL and 49% by DSM.
 
The name of the company (provisionally called NewCo) will be formed by combining DSM's business group DSM Pharmaceutical Products (DPP) and Patheon Inc, which NewCo has agreed to acquire for $ 9.32 per share in cash - resulting in a total enterprise value for Patheon of approximately $ 1.95 billion.
 
NewCo will be a leading global contract development and manufacturing organisation with anticipated 2014 sales of about $2 billion (pro-forma) and a strong EBITDA and operational cash flow. NewCo will have an end-to-end offering from finished dosage (drug products) to active substances (APIs) and a global footprint of 23 locations across North America, Europe, Latin America and Australia with about 8,300 employees.
 
ALSO READ: Ipca Labs to acquire 50% stake in Avik Pharmaceutical

Combining DPP and Patheon is fully in line with DSM's strategy for its pharma cluster as well as an excellent value creation opportunity as DSM and JLL will work together to maximize the value of NewCo. For DSM, combining DPP with Patheon into NewCo is also a key step in the strategic transformation of its pharma activities into partnerships.
 
Once the transaction is complete, NewCo will add scale and new value chain capabilities/technologies to expand its end-to-end service offering as a comprehensive solution provider to the industry. NewCo will operate as an independent standalone company.